
Ardelyx Investor Relations Material
Latest events

Q2 2025
Ardelyx
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Ardelyx Inc
Access all reports
Ardelyx Inc is a biopharmaceutical company engaged in discovering, developing, and commercializing novel treatments for patients with gastrointestinal and cardiorenal diseases. Their approach focuses on creating targeted, first-in-class, oral, small molecule therapies that address significant unmet medical needs. The company's flagship product candidate is tenapanor, aimed at treating irritable bowel syndrome with constipation. Furthermore, Ardelyx is advancing XPHOZAH in Phase III clinical trials for controlling serum phosphorus in patients with chronic kidney disease on dialysis, and other product candidates like RDX013 and RDX020 target hyperkalemia and metabolic acidosis, respectively. Ardelyx has formed strategic partnerships with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in various territories. Originally founded as Nteryx, Inc., the company rebranded to Ardelyx, Inc. in 2008 and is headquartered in Waltham, Massachusetts, with its shares listed on the NASDAQ.
Key slides for Ardelyx Inc


Corporate Presentation
Ardelyx Inc


Corporate Presentation
Ardelyx Inc
Latest articles
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
Ticker symbol
ARDX
Country
🇺🇸 United States